Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
13 March 2017 |
Main ID: |
EUCTR2016-002934-57-DE |
Date of registration:
|
03/11/2016 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
This is a study to evaluate the long-term safety, tolerability and efficacy of bimekizumab in adult patients with chronic plaque psoriasis.
|
Scientific title:
|
A multicenter, 48-week, open-label extension study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis.
|
Date of first enrolment:
|
22/02/2017 |
Target sample size:
|
45 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002934-57 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 1
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Australia
|
Canada
|
Georgia
|
Germany
|
Moldova, Republic of
|
Romania
|
United States
| |
Contacts
|
Name:
|
Clin Trial Reg & Results Disclosure
|
Address:
|
Alfred-Nobel-Strasse 10
40789
Monheim
Germany |
Telephone:
|
|
Email:
|
clinicaltrials@ucb.com |
Affiliation:
|
UCB Biosciences GmbH |
|
Name:
|
Clin Trial Reg & Results Disclosure
|
Address:
|
Alfred-Nobel-Strasse 10
40789
Monheim
Germany |
Telephone:
|
|
Email:
|
clinicaltrials@ucb.com |
Affiliation:
|
UCB Biosciences GmbH |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Subject must have completed all dosing requirements in PS0016 without meeting any withdrawal criteria
- Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug, and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose
- Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication (anticipated 5 half-lives) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5
Exclusion criteria: - Subjects previously participating in this study
- Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject’s ability to participate in this study. Note: For any subject with an ongoing serious adverse event (SAE), or a history of serious infections (including herpes zoster or hospitalizations) in PS0016, the Medical Monitor must be consulted prior to the subject’s entry into PS0018
- Subject has any current sign or symptom that may indicate a medically significant infection
- Subject has current clinically active infection with Histoplasma, Coccidiodes, Paracoccidioides, Pneumocystis, tuberculosis (TB), nontuberculous mycobacteria (NTMB),Blastomyces, Aspergillus, or Candidiasis (systemic). Any subject diagnosed with Histoplasmosis, Coccidiodes, Paracoccidiodes, Pneumocystis, TB, NTMB, Blastomyces, Aspergillus, or Candidiasis (systemic) during PS0016 is excluded from PS0018 even if treatment has been completed.
- Any subject who meets any withdrawal criteria in the feeder study (PS0016) is excluded from participating in the open-label extension study (PS0018)
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Chronic Plaque Psoriasis MedDRA version: 19.1
Level: LLT
Classification code 10071117
Term: Plaque psoriasis
System Organ Class: 100000004858
|
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
|
Intervention(s)
|
Product Name: Bimekizumab Product Code: UCB4940 Pharmaceutical Form: Solution for injection INN or Proposed INN: Bimekizumab CAS Number: 1418205-77-2 Other descriptive name: UCB4940 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 160-
|
Primary Outcome(s)
|
Primary end point(s): Incidence of Treatment Emergent Adverse Events (TEAEs) adjusted by duration of subject exposure to treatment
|
Main Objective: The primary objective of the study is to assess the long-term safety and tolerability of bimekizumab.
|
Secondary Objective: - assess the safety and tolerability of increasing the dose of bimekizumab from dose 1 every four weeks (Q4W) to dose 2 Q4W for subjects with an inadequate response at Week 12 - assess pharmacokinetics (PK) of bimekizumab - assess the immunogenicity of bimekizumab - assess the efficacy of open-label bimekizumab dose 1 Q4W administered over 48 weeks
|
Timepoint(s) of evaluation of this end point: From Baseline (Week 0) until Safety Follow Up Visit (up to Week 64)
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: NAP
|
Secondary end point(s): NAP
|
Source(s) of Monetary Support
|
UCB Biopharma SPRL
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|